{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T19:27:20Z","timestamp":1772220440763,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Science Foundation of the First Affiliated Hospital of Harbin Medical University","award":["2024M25"],"award-info":[{"award-number":["2024M25"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00277-025-06384-0","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T08:49:45Z","timestamp":1745830185000},"page":"2915-2926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation"],"prefix":"10.1007","volume":"104","author":[{"given":"Jie","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanxi","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiwen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"6384_CR1","doi-asserted-by":"publisher","first-page":"103753","DOI":"10.1016\/j.critrevonc.2022.103753","volume":"177","author":"R Bhattacharjee","year":"2022","unstructured":"Bhattacharjee R et al (2022) Theragnostic strategies harnessing the self-renewal pathways of stem-like cells in the acute myeloid leukemia. Crit Rev Oncol Hematol 177:103753","journal-title":"Crit Rev Oncol Hematol"},{"issue":"19","key":"6384_CR2","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1158\/1078-0432.CCR-22-1881","volume":"28","author":"DA Adrianzen-Herrera","year":"2022","unstructured":"Adrianzen-Herrera DA, Shastri A (2022) Unrelated Allogeneic Stem Cell Transplant in Relapsed\/Refractory AML: Widening the Yellow Brick Road. Clin Cancer Res 28(19):4167\u20134170","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6384_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","volume":"22","author":"T Sauerer","year":"2023","unstructured":"Sauerer T, Vel\u00e1zquez GF, Schmid C (2023) Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy. Mol Cancer 22(1):180","journal-title":"Mol Cancer"},{"issue":"11","key":"6384_CR4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41409-018-0171-z","volume":"53","author":"M Horowitz","year":"2018","unstructured":"Horowitz M et al (2018) Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant 53(11):1379\u20131389","journal-title":"Bone Marrow Transplant"},{"issue":"32","key":"6384_CR5","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","volume":"31","author":"SD Freeman","year":"2013","unstructured":"Freeman SD et al (2013) Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 31(32):4123\u20134131","journal-title":"J Clin Oncol"},{"issue":"31","key":"6384_CR6","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","volume":"31","author":"M Terwijn","year":"2013","unstructured":"Terwijn M et al (2013) High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J Clin Oncol 31(31):3889\u20133897","journal-title":"J Clin Oncol"},{"issue":"3","key":"6384_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/cncr.30361","volume":"123","author":"F Ravandi","year":"2017","unstructured":"Ravandi F et al (2017) Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer 123(3):426\u2013435","journal-title":"Cancer"},{"issue":"16","key":"6384_CR8","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F et al (2018) Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 132(16):1703\u20131713","journal-title":"Blood"},{"issue":"7","key":"6384_CR9","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","volume":"23","author":"BM Getta","year":"2017","unstructured":"Getta BM et al (2017) Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation. Biol Blood Marrow Transplant 23(7):1064\u20131071","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"6384_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","volume":"35","author":"M Balsat","year":"2017","unstructured":"Balsat M et al (2017) Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. J Clin Oncol 35(2):185\u2013193","journal-title":"J Clin Oncol"},{"issue":"9","key":"6384_CR11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood.2019002959","volume":"135","author":"R Dillon","year":"2020","unstructured":"Dillon R et al (2020) Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood 135(9):680\u2013688","journal-title":"Blood"},{"issue":"5","key":"6384_CR12","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ajh.27259","volume":"99","author":"C Orvain","year":"2024","unstructured":"Orvain C et al (2024) Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS\/AML or AML. Am J Hematol 99(5):862\u2013870","journal-title":"Am J Hematol"},{"key":"6384_CR13","doi-asserted-by":"crossref","unstructured":"Czyz A, Nagler A (2019) The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. Int J Mol Sci 20(21).","DOI":"10.3390\/ijms20215362"},{"issue":"8","key":"6384_CR14","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3324\/haematol.2018.208454","volume":"104","author":"NJ Short","year":"2019","unstructured":"Short NJ, Ravandi F (2019) How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? Haematologica 104(8):1532\u20131541","journal-title":"Haematologica"},{"issue":"26","key":"6384_CR15","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M et al (2021) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138(26):2753\u20132767","journal-title":"Blood"},{"issue":"10","key":"6384_CR16","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1038\/sj.leu.2402675","volume":"16","author":"D Cilloni","year":"2002","unstructured":"Cilloni D et al (2002) Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16(10):2115\u20132121","journal-title":"Leukemia"},{"issue":"5","key":"6384_CR17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1365-2141.2004.04952.x","volume":"125","author":"M \u00d8stergaard","year":"2004","unstructured":"\u00d8stergaard M et al (2004) WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol 125(5):590\u2013600","journal-title":"Br J Haematol"},{"issue":"1","key":"6384_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11864-019-0695-5","volume":"21","author":"S Schwind","year":"2020","unstructured":"Schwind S et al (2020) Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy. Curr Treat Options Oncol 21(1):8","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"6384_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-021-00500-9","volume":"11","author":"HJ Kim","year":"2021","unstructured":"Kim HJ et al (2021) Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Blood Cancer J 11(6):109","journal-title":"Blood Cancer J"},{"issue":"1","key":"6384_CR20","doi-asserted-by":"publisher","first-page":"e35641","DOI":"10.1002\/cncr.35641","volume":"131","author":"C Zhang","year":"2025","unstructured":"Zhang C et al (2025) Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia. Cancer 131(1):e35641","journal-title":"Cancer"},{"issue":"10","key":"6384_CR21","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.bbmt.2019.05.033","volume":"25","author":"BS Cho","year":"2019","unstructured":"Cho BS et al (2019) WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates. Biol Blood Marrow Transplant 25(10):1925\u20131932","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"6384_CR22","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short NJ et al (2020) Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol 6(12):1890\u20131899","journal-title":"JAMA Oncol"},{"key":"6384_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.999822","volume":"12","author":"JM Tettero","year":"2022","unstructured":"Tettero JM et al (2022) Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis. Front Oncol 12:999822","journal-title":"Front Oncol"},{"key":"6384_CR24","doi-asserted-by":"publisher","first-page":"677833","DOI":"10.3389\/fonc.2021.677833","volume":"11","author":"FJ Liu","year":"2021","unstructured":"Liu FJ et al (2021) Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia. Front Oncol 11:677833","journal-title":"Front Oncol"},{"issue":"1","key":"6384_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/leu.2014.173","volume":"29","author":"RB Walter","year":"2015","unstructured":"Walter RB et al (2015) Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 29(1):137\u2013144","journal-title":"Leukemia"},{"issue":"12","key":"6384_CR26","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41408-017-0007-x","volume":"7","author":"M Norkin","year":"2017","unstructured":"Norkin M et al (2017) Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. Blood Cancer J 7(12):634","journal-title":"Blood Cancer J"},{"issue":"7","key":"6384_CR27","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/leu.2016.46","volume":"30","author":"Y Zhou","year":"2016","unstructured":"Zhou Y et al (2016) Pre- and post-transplant quantification of measurable ('minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia 30(7):1456\u20131464","journal-title":"Leukemia"},{"issue":"12","key":"6384_CR28","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ et al (2018) Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131(12):1275\u20131291","journal-title":"Blood"},{"issue":"6","key":"6384_CR29","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1365-2141.2009.07770.x","volume":"146","author":"DA Jacobsohn","year":"2009","unstructured":"Jacobsohn DA et al (2009) High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol 146(6):669\u2013674","journal-title":"Br J Haematol"},{"issue":"2","key":"6384_CR30","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/j.clml.2020.09.008","volume":"21","author":"V Valkova","year":"2021","unstructured":"Valkova V et al (2021) WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience. Clin Lymphoma Myeloma Leuk 21(2):e145\u2013e151","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"6384_CR31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/cam4.593","volume":"5","author":"M Malagola","year":"2016","unstructured":"Malagola M et al (2016) Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients. Cancer Med 5(2):265\u2013274","journal-title":"Cancer Med"},{"key":"6384_CR32","doi-asserted-by":"publisher","first-page":"1340909","DOI":"10.3389\/fonc.2024.1340909","volume":"14","author":"S Ahmed","year":"2024","unstructured":"Ahmed S et al (2024) Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia. Front Oncol 14:1340909","journal-title":"Front Oncol"},{"key":"6384_CR33","doi-asserted-by":"crossref","unstructured":"Meddi E et al (2023) Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML. Int J Mol Sci 24(4).","DOI":"10.3390\/ijms24043062"},{"issue":"13","key":"6384_CR34","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M et al (2018) Molecular Minimal Residual Disease in Acute Myeloid Leukemia. N Engl J Med 378(13):1189\u20131199","journal-title":"N Engl J Med"},{"key":"6384_CR35","doi-asserted-by":"crossref","unstructured":"Vonk CM et al (2021) Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia. Cancers (Basel) 13(21).","DOI":"10.3390\/cancers13215431"},{"issue":"6","key":"6384_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1097\/MOH.0000000000000464","volume":"25","author":"RM Shapiro","year":"2018","unstructured":"Shapiro RM, Kim DDH (2018) Next-generation sequencing-based minimal residual disease monitoring in patients receiving allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome. Curr Opin Hematol 25(6):425\u2013432","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"6384_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bbmt.2014.10.026","volume":"21","author":"P Vyas","year":"2015","unstructured":"Vyas P, Appelbaum FR, Craddock C (2015) Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 21(1):8\u201315","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"6384_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cytob.21134","volume":"86","author":"W Zeijlemaker","year":"2014","unstructured":"Zeijlemaker W, Gratama JW, Schuurhuis GJ (2014) Tumor heterogeneity makes AML a \u201cmoving target\u201d for detection of residual disease. Cytometry B Clin Cytom 86(1):3\u201314","journal-title":"Cytometry B Clin Cytom"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06384-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06384-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06384-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:42Z","timestamp":1749105462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06384-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6384"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06384-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have consented for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}